While immunotherapy has transformed the clinical landscape for various solid malignancies, most notably melanoma and lung cancer, pancreatic ductal adenocarcinoma (PDAC) remains exceptionally recalcitrant to these T-cell-activating modalities. This profound […]

Immunotherapy, a type of treatment aimed at engaging the immune system – namely, T cells – to attack and kill cancer cells, has had success and redefined care in multiple […]

Pancreatic cancer is still one of the most lethal cancers, in part, because it has spread or metastasized by the time it is diagnosed. One common site of metastasis for […]

Chimeric antigen receptor (CAR) T cells, an immunotherapy that has been successful in treating blood cancers, has had limited efficacy in solid tumors including in pancreatic cancer. Greg Allen, MD, […]

Pancreatitis or inflammation of the pancreas comes in both acute and chronic forms and has long been appreciated as a risk factor for developing pancreatic cancer. While common and in […]

While the 5-year survival rate for pancreatic cancer has increased over the last decade to 13%, it continues to be one of the toughest cancers to diagnose and treat. One […]